Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist.
J Asian Nat Prod Res
; 25(5): 484-496, 2023 May.
Article
in En
| MEDLINE
| ID: mdl-35866240
ABSTRACT
Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
PPAR gamma
/
Obesity
Limits:
Animals
Language:
En
Journal:
J Asian Nat Prod Res
Journal subject:
BOTANICA
/
QUIMICA
Year:
2023
Document type:
Article
Affiliation country: